galcanezumab

Details

Generic Name:

galcanezumab

Project Status:

Not filed

Therapeutic Area:

Episodic cluster headache

Manufacturer:

Eli Lilly Canada Inc.

Brand Name:

Emgality

Project Line:

Reimbursement Review

Project Number:

N/A

Submission Type:

Non Submission

Indications:

The reduction in the frequency of attacks throughout a cluster period in adults with episodic cluster headache with prior cluster headache periods lasting at least 6 weeks and who have had an inadequate response to, or tolerated poorly, or had contraindications to conventional preventive therapies established by Canadian practice guidelines.

Recommendation Type:

CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer

Last Updated : August 3, 2021